Biocept Ceo

Nall as President and Chief Executive Officer. About Biocept. Michael Goldberg has served as a member of our board of directors since November 2011. The Wall Street Transcript is a completely unique resource for investors and business researchers. However, sales failed to impress the street. (NASDAQ:BIOC) in 2013. 14, 2018 /PRNewswire/ -- Biocept, Inc. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecula. CURRENT PRICE. Feb 4, 2020 8:05AM EST. 8 million during 4Q 2019, an increase of 108% over the same period last year, before it unveiled a second contract for its assay services with California independent physician. Biocept, Inc. 5810 Nancy Ridge Dr. If you have patients who need laboratory testing by Biocept and who may not be able to come to your office for a blood draw, please contact our customer. See the complete profile on LinkedIn and discover Bruce A'S. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. was founded in 1997 and is headquartered in San Diego, California. Its revenue is up 2. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities. Biocept Inc (NASDAQ:BIOC) a major commercial provider of liquid biopsy assessments intended to offer physicians with clinically actionable data to enhance the outcomes of cancer patients, reported that CEO and President W. Jody Cain - LHA, IR. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. SAN DIEGO, Feb. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. 7, 2019 /PRNewswire/ -- Biocept, Inc. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. Find CEO contacts. 4, 2020 /PRNewswire/ -- Biocept, Inc. Find CEO in Medical Testing & Clinical Laboratories contacts. (BIOC) Michael W. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire - Tue Feb 4, 7:05AM CST CMTX - Tue Feb 4, 7:05AM CST Biocept, Inc. The collaborators will validate the use of Thermo Fisher's Oncomine NGS liquid biopsy panels at. announced today that it has appointed Michael W. This differentiates Biocept from similar companies and allows Biocept to capture a broader array of CTCs. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. All content is posted anonymously by employees working at Biocept. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Common Stock (BIOC) Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Biocept, Inc. is a commercial stage oncology diagnostics company. ET on Seeking Alpha Biocept (BIOC) Receives a Buy from Maxim Group. 20 per share on revenue of $1. via Skype, and they discuss. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept Inc (NASDAQ: BIOC) is having a rough start to the trading session, down about 2. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. SAN DIEGO, Jan. Over the last four quarters, Biocept's revenue has grown by 74. Biocept, Inc. The company's cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. The MarketWatch News Department was not involved in the creation of this content. Dunn has served as Biocept's Vice President of Commercial Operations since October 2018. Biocept Logo (PRNewsFoto/Biocept, Inc. Nall says, along these lines, Biocept was recently awarded a patent. 46,233 people own Biocept on Robinhood on May 6, 2020. According to present data Biocept's BIOC shares and potentially its market environment have been in bearish cycle last 12 months (if exists). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept also began the year aiming to improve the collections and billing system with a view to making it more efficient and effective. About Biocept. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. (the "Company") sets high standards for the Company's employees, officers and directors. There are 4 older and 6 younger executives at Biocept. April 29, 2020 Comments Off on fuboTV (OTC: FBNK) CEO David Gandler Featured by Wedbush Securities Managing Director of Digital Media Equity Research Michael Pachter in Public Company Spotlight ImagineAR (OTC: IPNFF) Signs Five Year $300,000USD Licensing Agreement with SlapItOn to Provide Augmented Reality for Athletes and Celebrities to Engage. is a commercial-stage cancer diagnostics company. SAN DIEGO, April 20, 2020 /PRNewswire/ -- Biocept, Inc. “The launch of our liquid biopsy kit strategy has been a priority for Biocept, and we are excited to now have the ability to leverage the value of our patents as we enable laboratories around the world to utilize our proprietary Target Selector technologies,” said Michael Nall, president and CEO of Biocept in a press release. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive's Steve Darling with news the company can start selling their Target Selector molecula. 0 Million Underwritten. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. 11, 2020 12:11 PM ET. The presence of tumor cells in #CSF may be an indicator that cancer has spread into the central nervous system (CNS). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Please don't submit any personal information. 4, 2020 /PRNewswire/ -- Biocept, Inc. "I'm exceptionally proud of our strong operational performance throughout 2019 and into 2020," Biocept CEO Mike Nall has said. (NASDAQ:BIOC) in 2013. 00 per share. stock and Diagnostics & Research market discussion, news, and analysis from Canada's largest community of active investors Stockhouse. Biocept, Inc. (NASDAQ:BIOC) marked $0. Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc. company's chief financial officer since 2012. Join to Connect. NasdaqCM:BIOC CEO Compensation, October 14th 2019. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. The following slide deck was published by Biocept, Inc. 0 on Oct 28. 46,233 people own Biocept on Robinhood on May 6, 2020. Tim Kennedy - SVP, Operations. SA Breaking News. Biocept President and CEO Michael Nall stated, "We are very pleased to make our Target Selector™ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer. 12/12/2019: 07:00: PRNUS: Biocept Announces Closing of $10. Wainwright Global. View the real-time BIOC price chart on Robinhood and decide if you want to buy or sell commission-free. Biocept, Inc. The one-year performance of Biocept Inc. (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. Biocept earned a media sentiment score of 2. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. Mike Nall has been the CEO of Biocept, Inc. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016. According to present data Biocept's BIOC shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Dunn has served as Biocept's Vice President of Commercial Operations since October 2018. This analysis aims first to contrast CEO compensation. Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. (NASDAQ:BIOC) since 2013. The Wall Street Transcript is a completely unique resource for investors and business researchers. is a commercial-stage cancer diagnostics company. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Wilkins EVP, COO UNITED FIRE GROUP INC: Michael Toh Kok Soon CEO and President TOGA LTD: Michael V. stock is -60. B Units,and other labs equipments. via Skype, and they discuss. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network - Yahoo Finance. Nall has issued the following letter to stockholders:. 00 per share. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. At the time of writing our data says that Biocept, Inc. Athersys was moving up 8. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. CURRENT PRICE. Biocept, Inc. 2/20/2019 8:06:06 AM Biocept President And CEO Michael Nall Issues Letter To Stockholders 2/8/2019 8:52:14 AM Biocept Reports Pricing Of $7. About Biocept. (NASDAQ:BIOC) in 2013. Hale served as Hybritech’s president, COO, and CEO. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. PredictMedix (CSE: PMED-OTCQB: PMEDF) CEO Dr Rahul Kushwah joined Steve Darling from Proactive Vancouver with news the company has signed a deal with healthcare giant Max to bring their technology to India. Biocept expands uses for its Target Selector liquid biopsy tech, expands Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and. , a Chairman at Recros Medica, Inc. Reiss, Chairman of the Board. We are working on Hematology Analyzers, Chemistry Analyzers, Clinical Chemistry Kits, Hematology Reagents, Plate Readers, Washers, H. Jody Cain - LHA, IR. About BIO CEO & Investor Conference The BIO CEO and Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire - Tue Feb 4, 7:05AM CST CMTX - Tue Feb 4, 7:05AM CST Biocept, Inc. The Day Ahead newsletter:. 11, 2020 12:11 PM ET. Biocept Inc is based in San Diego, CA. Focused on management and leadership of the translational research team in optimizing and validating laboratory tests for commercialization through Biocept's CAP. 8225 Email: [email protected] "Our new dual sample kit offers researchers and assay developers. Your question will be posted publicly. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 - StreetInsider. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 02% gain, an insight into the fundamental values of Biocept, Inc. Awarded United States Patent for the. To access Person ’s phone and email just run the installation wizard and get the ZoomInfo Community Edition. Report this profile; Activity. B Units,and other labs equipments. Securities products and services offered to self-directed investors through ST Invest, LLC. Why Biocept, Inc. NasdaqCM:BIOC CEO Compensation, October 14th 2019. “We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform,” Sundeep Bhan, Co-founder and CEO of Prognos said. CEO Michael Nall said following this announcement, “We believe that our pathology partnership platform offers urologists and uropathologists a unique solution to evaluate and treat their patients diagnosed with prostate cancer, which further distinguishes Biocept from other commercial liquid biopsy services. Nall announced that to spearhead the improvements would be Tim Kennedy, the company's operations vice president and chief financial officer, who joined the company a little over six months ago. Biocept, Inc () Stock Market info Recommendations: Buy or sell Biocept stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biocept share forecasts, stock quote and buy / sell signals below. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. Hale is a Chairman at Adigica Health, Inc. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. Biocept, Inc. has a market cap of US$13m, and reported total annual CEO compensation of US$440k for the year to December 2018. 78% of Nall's compensation, or $617. From January 2005 to May 2011, Mr. The company had less than $2. Biocept News. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. Nall announced that to spearhead the improvements would be Tim Kennedy, the company’s operations vice president and chief financial officer, who joined the company a little over six months ago. Added Biocept President and CEO Michael Nall: “The results of this large-scale study with renowned oncology centers could further validate the extremely high sensitivity and specificity that we have demonstrated with our Target Selector platform in past studies. Biocept has partnered with a national clinician network to accept patient samples and may obtain additional agreements as test capacity is increased. Biocept, Inc. BIO CEO & Investor Conference Feb 8-9, 2021 New York, New York. Source: StreetInsider Press Release: Biocept : Biocept Announces Pricing of $2. Focused on management and leadership of the translational research team in optimizing and validating laboratory tests for commercialization through Biocept's CAP. Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans. The top 10 competitors average 48. Biocept Stock Price Forecast, BIOC stock price prediction. Biocept nabs new patent in Brazil; shares up 15% premarket: 03/25/2020 08:15 PM EDT: SeekingAlpha : Biocept, Inc. Steps Into Limelight as CEO. Nall will present a corporate. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. com Phone Number 858-320-8200 Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and. Mike Nall has been the CEO of Biocept, Inc. 5810 Nancy Ridge Dr. Focused on management and leadership of the translational research team in optimizing and validating laboratory tests for commercialization through Biocept's CAP. , while the value can represent an indicator in the future growth. Investing in securities products involves risk, including possible loss of principal. 5% as of 11:41 a. 02, beats on revenue Seeking Alpha Nov 13, 2019 Biocept files. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. On March 28, 2017, Biocept, Inc. Approves of CEO. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. -China trade as planned tariffs on Chinese imports kick in on Dec. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Kevin McCabe - LHA, IR. 14, 2020 /PRNewswire/ -- Biocept, Inc. Ibio Earnings Date. "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial. Biocept, Inc. 12/12/2019: 07:00: PRNUS: Biocept Announces Closing of $10. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. There are 4 older and 6 younger executives at Biocept. Here’s what’s going on: Stop wasting your time!. "We are pleased to welcome Dr. 0 while NAPOLITAN RAYMOND S JR, (Executive Vice President) sold 7,214 shares on Jul 24. “Results of this study could open new market opportunities for Biocept,” Michael W. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the. 5810 Nancy Ridge Drive San Diego, CA 92121 (858) 320-8200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to:. Biocept, Inc BIOC CEO Michael Nall on Q4 2019 Results - Duration: 42:41. 3% to 58 cents at the time of publication Monday. The gains come after the company said that it has been granted a new patent. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Our first product is the PURE EP™ System, a system designed for use in the large and growing electrophysiology market. 0 Million Underwritten. Biocept, Inc. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. San Diego’s Biocept Inc. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial. The gains come after the company announced the validation and availability of a new liquid biopsy. Member FINRA / SIPC. Their average twelve-month price target is $1. Their patented Target-Selector Assays for ctDNA use real-time PCR, Sanger sequencing and next generation sequencing (NGS). Biocept has implemented use of cocktails of antibodies for the capture and enrichment of cells of interest. (BIOC) is based in the USA and it represents one of the well-known company operating with Healthcare sector. Biolase is a global leader in dental lasers and products that provide biological treatments to reduce pain and improve dental patient safety. 4, 2020 /PRNewswire/ -- Biocept, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. (NASDAQ:BIOC) since 2013. The one-year performance of Biocept Inc. Get the latest MicroCap stock market news, information, insights on Stock News Now. Griffin Regional President (Americas) HILL INTERNATIONAL INC: Michael W. has grown earnings per share (EPS) by 69% each year (using a line of best fit). The shares were sold at $54. 53M shares in trading volumes in the last trading session, way higher than the average trading volume of 15. Industry, sector and description for Biocept. Biocept News. Growing? On average over the last three years, Biocept, Inc. Feb 9 (Reuters) - Biocept Inc * Biocept’s CEO issues letter to stockholders * Biocept- Later in year, plan to initiate commercial pilot program for hospital-based pathologists to interpret. SAN DIEGO, Nov. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 2M; in Q1 2019, Biocept's revenue was $1M. Nall announced that to spearhead the improvements would be Tim Kennedy, the company's operations vice president and chief financial officer, who joined the company a little over six months ago. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Ask a question. com - 14 - Shares of Biocept Inc. Nall President and Chief Executive Officer About Biocept Biocept, Inc. Please wait while we load your information from QuoteMedia. Mike Nall has been the CEO of Biocept, Inc. (Shutterstock) SAN DIEGO, CA — A San Diego-based molecular. Common Stock (BIOC) Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Biocept, Inc. Biocept, Inc. STOCKS ON THE MOVE-Canopy Growth, Diplomat Pharmacy, PG&E, Biocept, Synthorx. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix. The declines come after the company issued its financial results, leaving investors with mixed feelings. (BIOC) on CEO. We are working on Hematology Analyzers, Chemistry Analyzers, Clinical Chemistry Kits, Hematology Reagents, Plate Readers, Washers, H. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. Biocept, Inc. Michael Nall, CEO & President, Director at Biocept (BIOC), is currently unranked, see this insider's latest transactions. Welcome! Log into your account. Biocept now offers Target Selector™ Liquid Biopsy for the detection of circulating tumor cells (CTCs) and biomarkers in cerebrospinal fluid (CSF) for #lungcancer patients. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA. Compare pay for popular roles and read about the team's work-life balance. "Among notable accomplishments, we launched the first-and-only liquid biopsy test to evaluate cerebrospinal fluid as well as NGS test panels for lung and breast cancer. 12/12/2019: 07:00: PRNUS: Biocept Announces Closing of $10. Biocept Appoints Michael Nall as CEO September 10, 2013 02:36 PM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. SAN DIEGO, April 28, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. SAN DIEGO, Jan. com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO. (BIOC) Michael W. (NASDAQ:BIOC), a. See questions about. Biocept, Inc. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire +8. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Daily Earnings Calls 16 views. See the complete profile on LinkedIn and discover Bruce A'S. What is the work environment and culture like?. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016. 's ISS governance QualityScore as of N/A is N/A. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript biopharmaceutical companies and clinical trial support and specific oncogenic alterations. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. The company said that Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, connects physicians and their patients to its Labs-of-Choice network, which are preferred, high-quality laboratories that now including Biocept. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. The kits are intended to enable molecular laboratories to use Biocept's circulating-tumor DNA (ctDNA) assays in performing liquid biopsy testing Proactive's CEO Investor Sessions Melbourne. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. "Among notable accomplishments, we launched the first-and-only liquid biopsy test to evaluate cerebrospinal fluid as well as NGS test panels for lung and breast cancer. Biocept, Inc. BIOC stock has a five-year performance of -99. , according to the company’s website (see here: www. See the complete profile on LinkedIn and discover Bruce A'S. “We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform,” Sundeep Bhan, Co-founder and CEO of Prognos said. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. , a real estate investment trust. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. 00 and the low price target for BIOC is $1. com Facebook View on Facebook LinkedIn View on LinkedIn Twitter View on Twitter Contact Email [email protected] Notably, the salary of US$426k is the vast majority of the CEO compensation. Revenue grew 107. SAN DIEGO, Feb. Biocept will hold a conference call today at 4:30 p. Hale, 70 Non-Executive Chairman, Biocept, Inc. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. The MarketWatch News Department was not involved in the creation of this content. Biocept Inc (NASDAQ: BIOC) is having a rough start to the trading session, down about 2. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with. Following a year of bearish outlook on the company’s share price, Biocept Inc (NASDAQ:BIOC) is currently basking in the glory of their bull run. Biocept, Inc () Stock Market info Recommendations: Buy or sell Biocept stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biocept share forecasts, stock quote and buy / sell signals below. 4, 2020 /PRNewswire/ -- Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and. Website www. Biocept Inc (NASDAQ:BIOC) a major commercial provider of liquid biopsy assessments intended to offer physicians with clinically actionable data to enhance the outcomes of cancer patients, reported that CEO and President W. See the complete profile on LinkedIn and discover Bruce A’S. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecula. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. --Biocept, Inc. Hale was appointed Executive Chairman of Biocept in March 2011. is a commercial-stage cancer diagnostics company. Here's what's going on: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!. Comprehensive Genomic Profiling. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. A free inside look at company reviews and salaries posted anonymously by employees. Biocept, Inc. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Michael W Nall is President/CEO at Biocept Inc. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. "I'm exceptionally proud of our strong operational performance throughout 2019 and into 2020," Biocept CEO Mike Nall has said. 4, 2020 at 8:05 a. 29 and move down -593. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive's Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. Biocept, Inc. SAN DIEGO, Feb. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Market Data by Xignite and BATS BZX Real-Time Price. Mike Nall has been the CEO of Biocept, Inc. NasdaqCM:BIOC CEO Compensation, October 14th 2019. LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. The gains come after the company announced the validation and availability of a new liquid biopsy. Frey also served as a board member at Vitesse Semiconductor. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. Biocept now offers Target Selector™ Liquid Biopsy for the detection of circulating tumor cells (CTCs) and biomarkers in cerebrospinal fluid (CSF) for #lungcancer patients. com email addresses and possibly Michael Nall's email. 4 Biocept reviews. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. Biocept (BIOC) reported a Quarter December 2019 loss of $0. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. At the time of writing, our data says that Biocept, Inc. Your question will be posted publicly. The designation allows Biocept to sell its kits throughout the European Union and other CE mark geographies. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Subscribe now!. Wainwright Global. Feb 9 (Reuters) - Biocept Inc * Biocept’s CEO issues letter to stockholders * Biocept- Later in year, plan to initiate commercial pilot program for hospital-based pathologists to interpret. 5M; in Q2 2019, it was $1. Terry has vast leadership experience managing large and small commercial teams. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript. 76% Jan-14-20 08:05AM Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid PR Newswire +14. Tim Kennedy - SVP, Operations. Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) Strategy. Coutts, who was named as Biocept’s CEO in 2008, told me he had just lost a daughter to cancer, and he convinced the board that cancer diagnostics was the best use of Biocept’s technology. More Recent News About Biocept Inc. (the "Company") sets high standards for the Company's employees, officers and directors. com Phone Number 858-320-8200 Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The oldest executive at Biocept, Inc. Specifically, in Q4 2019's revenue was $1. Michael Nall - President and CEO. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. "Among notable accomplishments, we launched the first-and-only liquid biopsy test to evaluate cerebrospinal fluid as well as NGS test panels for lung and breast cancer. The presence of tumor cells in #CSF may be an indicator that cancer has spread into the central nervous system (CNS). Hale was appointed Executive Chairman of Biocept in March 2011. It is Biocept’s. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. According to present data Biocept's BIOC shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Biocept, Inc. Share this article. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers in plasma circulating tumor DNA. : Scientist or Sr. and Oasis Biosciences, Inc. SAN DIEGO, Feb. (the "Company") sets high standards for the Company's employees, officers and directors. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference News provided by. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Next Super Stock – April 17, 2020 Livestream CytoDyn, Inc. Nall, Biocept’s President and CEO. ST Invest is a wholly owned subsidiary of StockTwits, Inc. 4, 2020 /PRNewswire/ -- Biocept, Inc. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. BioCryst shares were gaining 21. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. Biocept, Inc. Biocept also began the year aiming to improve the collections and billing system with a view to making it more efficient and effective. your username. At the time of writing, our data says that Biocept, Inc. BIOC, a molecular diagnostics company commercializing and developing blood-based biomarkers to improve. Company Website. See what employees say about what it's like to work at Biocept. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K. has inked a deal with Scripps Health making Biocept the system’s preferred provider for cancer-related liquid biopsy tests. 4, 2020 at 8:05 a. Member FINRA / SIPC. Our first product is the PURE EP™ System, a system designed for use in the large and growing electrophysiology market. in conjunction with this event. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. Time (ET) Biocept to Present at the 22nd Annual BIO CEO & Investor Conference. > Biocept is changing the way physicians examine blood work for their cancer patients COVID-19 Coronavirus Outbreak – Latest Media Coverage Biocept is changing the way physicians examine blood work for their cancer patients. Biocept, Inc. Biocept, Inc. 67 per share on Oct 24 for a total of $421334. Linda Macander Executive Assistant to CEO at Biocept Greater San Diego Area Biotechnology. Prior to Biocept, he served as Executive Vice President of Sequenom, Inc. 8M; in Q3 2019, it was $1. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Subscribe now!. ET on Seeking Alpha Biocept (BIOC) Receives a Buy from Maxim Group. BIO CEO & Investor Conference Feb 8-9, 2021 New York, New York. Implicit in this philosophy is the importance of sound corporate governance. Biocept will hold a conference call today at 4:30 p. Griffin Regional President (Americas) HILL INTERNATIONAL INC: Michael W. 5K, was in option. San Diego Life Sciences Roundup: Evoke, Halozyme, Biocept, and More. The Chairman and CEO had earlier sold another 3,203 NUE shares valued at $172962. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. Common Stock (BIOC) Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Biocept, Inc. (NASDAQ:BIOC) Q4 2018 Results Earnings Conference Call March 28, 2019 4:30 PM ET Company Participants. Brazil Patent Granted for Biocept's Target Selector(TM) Oncogene Mutation Enrichment. We are working on Hematology Analyzers, Chemistry Analyzers, Clinical Chemistry Kits, Hematology Reagents, Plate Readers, Washers, H. Founder of Molecular Biosystems, Inc. Biocept, Inc. 7729 Company Operator: 858. Your question will be posted publicly. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. Corporate governance Biocept, Inc. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. 5K, was in option. (NASDAQ: Selector™ assays to help physicians better understand treatment options for their patients with breast cancer," said Biocept's President and CEO Michael Nall. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 's ISS governance QualityScore as of N/A is N/A. I have been working at Biocept full-time (More than a year) Pros. Press Release Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Published: Feb. (NASDAQ:BIOC) since 2013. is the leading provider of real-time or delayed intraday stock and commodities charts and quotes. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network - Yahoo Finance. "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial. Its 52-week range is between 0. Biocept CEO Michael Nall Now the company has its eye on expansion, planning to roll out similar tests for colorectal cancer and melanomas in the year to come, CEO Michael Nall told. SAN DIEGO, Feb. Hale, 70 Non-Executive Chairman, Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. SAN DIEGO, April 20, 2020 /PRNewswire/ -- Biocept, Inc. Biocept, Inc. “The launch of our liquid biopsy kit strategy has been a priority for Biocept, and we are excited to now have the ability to leverage the value of our patents as we enable laboratories around the world to utilize our proprietary Target Selector technologies,” said Michael Nall, president and CEO of Biocept in a press release. InMed Pharmaceuticals Inc (CSE:IN) (OTCMKTS:IMLFF) CEO Eric Adams sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The following slide deck was published by Biocept, Inc. The Board of Directors of Biocept Inc. Biocept's President and CEO. 1 Biocept’s CEO Issues Letter to Stockholders Highlights key accomplishments and outlines value drivers for 2017 SAN DIEGO (February 9, 2017) - Biocept, Inc. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Biocept against related stocks people have also bought. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. Biocept Inc (NASDAQ:BIOC) announced Monday that a major laboratory-management provider now offers the company’s flagship liquid biopsy tests for patients with cancer. com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday. Jody Cain - LHA, IR. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript Mar. Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020 PR Newswire (US) - 4/29/2020 8:05:00 AM: Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 7:56:14 AM. has hired ex-Trovagene executive Michael Terry to join their leadership team as senior vice president of commercial operations. Frey also served as a board member at Vitesse Semiconductor. Find the latest press releases from Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and. (NASDAQ:BIOC) since 2013. Michael Nall - President & CEO. Biocept, Inc. The top 10 competitors average 48. Among the significant. Kevin McCabe - LHA, IR. NasdaqCM:BIOC CEO Compensation, October 14th 2019. “We are pleased to partner with Alliance Global to offer patients diagnosed with cancer access to our patented liquid biopsy testing,” said Michael Nall, President and CEO of Biocept. Hale was appointed Executive Chairman of Biocept in March 2011. The company had less than $2. in conjunction with this event. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire SAN DIEGO, Feb. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. (NASDAQ:BIOC) Q4 2019 Results Earnings Conference Call March 25, 2020 4:30 PM ET Company Participants. com - 14 - Shares of Biocept Inc. "We are excited to expand our work with Thermo Fisher by deriving synergies from the combination of cutting-edge technologies and services from both companies," said Biocept's President and CEO. Margaret Faye Wilson, 81 Lead Independent Director, Biocept, Inc. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. Genomic Testing. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Tim Kennedy - SVP, Operations. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. Reiss, Chairman of the Board. What happened. Biocept nabs new patent in Brazil; shares up 15% premarket: 03/25/2020 08:15 PM EDT: SeekingAlpha : Biocept, Inc. Biocept will hold a conference call today at 4:30 p. About Biocept. (NASDAQ:BIOC) in 2013. Liquid biopsy company Biocept Inc. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. 09/12/2019: 08:15: PRNUS. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. 67 %, while year-to-date (YTD) performance is 34. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept announces that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020. Biocept, Inc. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. Market Data by Xignite and BATS BZX Real-Time Price. Nall, the company's CEO, said in a statement. (BIOC) on CEO. Hale is a Chairman at Adigica Health, Inc. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. Tim Kennedy - SVP, Operations. 25, 2020 at 8:15 p. Nall is a healthcare executive with over 25 years of experience. 75% at the open. With having a 69. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. Mike Nall has been the CEO of Biocept, Inc. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. "We are pleased to reach an agreement with a second large California-based IPA, this one in the southern part of the state, to provide liquid biopsy services for patients diagnosed with cancer," said Michael Nall, Biocept's President and CEO. Biocept, Inc. Compare pay for popular roles and read about the team's work-life balance. "Our offerings provide evidence-based, clinically actionable results in a timely and cost-effective manner. 46,233 people own Biocept on Robinhood on May 6, 2020. 4 Biocept reviews. 333-234459 Dear Mr. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Biocept against related stocks people have also bought. 25, 2016 /PRNewswire/ -- Biocept, Inc. 11, 2020 12:11 PM ET. Notably, the salary of US$426k is the vast majority of the CEO compensation. San Diego Life Sciences Roundup: Evoke, Halozyme, Biocept, and More. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. The MarketWatch News Department was not involved in the creation of this content. 5810 Nancy Ridge Dr. Prior to Biocept, he served as Executive Vice President of Sequenom, Inc. In 2014, he led the company as the retailer's interim president and CEO from May to August while continuing to act as CFO. About BIO CEO & Investor Conference The BIO CEO and Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech. 36 closing price. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network - Yahoo Finance. Investing in securities products involves risk, including possible loss of principal. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of. ) "Testing the CSF for cancer biomarkers in patients suspected to have brain metastases can be important, as the rapid confirmation and characterization of CNS involvement enables appropriate treatment selection in a timely manner," stated Santosh Kesari, MD, PhD, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. View Bruce A Huebner’s profile on LinkedIn, the world's largest professional community. 00, suggesting that the stock has a possible upside of 158. View company web site for more details. Kevin McCabe - LHA, IR. is a commercial-stage cancer diagnostics company. The MarketWatch News Department was not involved in the creation of this content. Biocept, Inc. "We are pleased to welcome Dr. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. stock is -60. “We are pleased to partner with Alliance Global to offer patients diagnosed with cancer access to our patented liquid biopsy testing,” said Michael Nall, President and CEO of Biocept. Michael Goldberg has served as a member of our board of directors since November 2011. 0 on Oct 28. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with. 94%, while BIOC stocks collected +0. Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer. Here’s what’s going on: Stop wasting your time!. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. 7, 2019 /PRNewswire/ -- Biocept, Inc. The general public, who are mostly retail investors, collectively hold 70% of Biocept shares. (NASDAQ: Selector™ assays to help physicians better understand treatment options for their patients with breast cancer," said Biocept's President and CEO Michael Nall.